The central venous catheter market is valued at US$ 3.20 Billion in 2026 and is projected to reach US$ 5.01 Billion by 2033, growing at a CAGR of 6.6%, driven mainly by rising oncology infusion therapy demand and longer treatment durations.
Growth is driven by ICU capacity expansion post-pandemic and stricter infection control reporting requirements that push hospitals toward advanced antimicrobial catheter adoption.
Non-tunneled central venous catheters hold the largest share at 35.0% due to their rapid, bedside insertion capability in emergency and critical care settings.
North America leads with 40.0% share in 2026, supported by strong ICU infrastructure and reimbursement-linked infection control compliance programs.
The key opportunity lies in home infusion therapy and nurse-insertable PICC systems as healthcare shifts from hospital to outpatient care models.